Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Key Numbers
Market Cap
$750B
P/E
65
Revenue Growth
+32.0%
Gross Margin
N/A
ROE
N/A
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a mega-cap NYSE-listed company in the pharma space, blending biotech and genomics initiatives alongside its core business operations. Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs. Valued at 65x trailing earnings with a $750B market capitalization, Eli Lilly and Company has delivered rapid top-line expansion with revenue moving +32% over the past year.
Expert Coverage
Unlock Full LLY Analysis
Expert analysis and coverage for Eli Lilly and Company
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-05-14
More in Biotech & Genomics
ALNY
Alnylam Pharmaceuticals
90
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%CRSP
CRISPR Therapeutics
89
True North
Pure Play
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
NASDAQ
MCap $5BRev +350%BEAM
Beam Therapeutics
89
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3BDXCM
DexCom Inc.
89
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55